Skip to main content
Toggle navigation
Login
Home
iwCLL X / Twitter
Abstract Listing
Home
Abstract Listing
Abstract Listing
Type here to filter the list
Sort by
#
Sort by
Title
1001
IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
Oral Poster
Poster
Favorite
1003
A Phenotypically Distinct Population of CLL Cells with Lower CD20 Expression is Present Within Abdominal Subcutaneous Adipose Tissue of Patients with CLL
Poster
Favorite
1004
Ubiquitin-like post-translational modifications may modulate the pathogenesis of chronic lymphocytic leukemia mediated by RRAS2
Poster
Favorite
1005
hnRNPU regulates alternative splicing of Cav1.2 calcium channel: implications in ibrutinib-associated ventricular arrhythmia
Poster
Favorite
1006
ApoliproteinE induces ferroptosis in chronic lymphocytic leukaemia cells
Poster
Favorite
1007
Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches
Poster
Favorite
1008
Clinical characteristics and outcome of chronic lymphocytic leukemia patients with renal involvement in the era of target drugs
Poster
Favorite
1009
Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL
Poster
Favorite
1010
Toll-like receptor 9 signalling is a potential tumour escape mechanism following B-cell receptor targeted treatments in subsets of patients with Chronic Lymphocytic Leukaemia.
Poster
Favorite
1011
A Novel Preclinical Mouse Model of Chronic Lymphocytic Leukemia Driven by BCOR Loss in B Cells
Poster
Favorite
1012
Evidence For A Pre-Switched Population And Unmutated Immunoglobulin Receptors In IgG-Expressing CLL Stereotyped Subset #4
Poster
Favorite
1013
The S100A9/EMMPRIN axis is involved in chronic lymphocytic leukemia progression and offers novel therapeutic opportunities
Poster
Favorite
1014
Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance
Poster
Favorite
1015
Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
Poster
Favorite
1016
Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis
YIM Oral
Poster
Favorite
1017
Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells
YIM Oral
Poster
Favorite
1018
Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression
YIM Oral Poster
Poster
Favorite
1019
Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice
YIM Oral Poster
Poster
Favorite
1020
KRAS^G13D-Dependent PI3K/AKT Signaling Regulates Fatty Acid Oxidation in Chronic Lymphocytic Leukemia
YIM Oral Poster
Poster
Favorite
1021
Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL
YIM Oral Poster
Poster
Favorite
1022
Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
Oral
YIM Oral
Poster
Favorite
1023
Clinical and biological impact of MYC Overexpression in Chronic Lymphocytic Leukemia with and without TP53 Disruption
Oral
Favorite
1024
ROR1-Signaling Enhances Survival and Drug-Resistance of del(17p)/TP53-Mutated CLL by Mitigating Oxidative Stress Via Activation of NRF2
Oral
Favorite
1101
An immuno-(epi)genomic classification of chronic lymphocytic leukemia refines outcome prediction
Oral Poster
Poster
Favorite
1102
Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.
Oral Poster
YIM Oral Poster
Poster
Favorite
1103
Identification and multi-omic characterization of a novel molecular subtype of CLL based on EBF1 expression levels
Poster
Favorite
1104
A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)
Poster
Favorite
1105
Defining Signalotypes in Chronic Lymphocytic Leukemia and Applying Machine Learning to Better Characterize Biological and Clinical Subgroups
Poster
Favorite
1106
Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
Poster
Favorite
1107
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Poster
Favorite
1108
CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls
Poster
Favorite
1109
Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia
Poster
Favorite
1110
Clinical Profiles of Chronic Lymphocytic Leukemia Patients with SF3B1 Mutations: A Single-Institution Study
Poster
Favorite
1111
Functional analysis of in-frame variants in TP53 gene identified in adult leukemias: A study of the TP53 Network of European Research Initiative on CLL
Poster
Favorite
1112
Artificial Intelligence–Driven Clustering of Peripheral Blood Cell Morphology Reveals Disease Heterogeneity and Prognostic Relevance in CLL
Poster
Favorite
1113
Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis
Poster
Favorite
1114
Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes
Poster
Favorite
1115
Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance
Poster
Favorite
1116
IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment
Poster
Favorite
1117
The clinical significance of specific SF3B1 mutation variants in Chinese patients with chronic lymphocytic leukemia
Poster
Favorite
1118
Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53
Poster
Favorite
1119
MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
YIM Oral Poster
Poster
Favorite
1120
Serum LC-MS based untargeted metabolomics machine learning for distinguishing asymptomatic and symptomatic CLL/SLL and predicting TTFT
YIM Oral Poster
Poster
Favorite
1121
High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.
Oral
Favorite
1122
Integrative epi(genome) analysis of CD49d bimodal expression reveals epigenetically driven phenotypic transitions in CLL
Oral
Favorite
1201
IFNγ/IL21-JAK-STAT1 Signaling Axis Drives T-Cell–Mediated CLL Proliferation and Venetoclax Resistance
Oral Poster
YIM Oral
Poster
Favorite
1202
Advanced 3D culture system revealed the dynamic regulation of Podoplanin in CLL cells within the microenvironment
Poster
Favorite
1203
SF3B1 K700E Mutation Promotes SAT1-Mediated Metabolic Reprogramming and Suppresses T-cell Immune Response in Chronic Lymphocytic Leukemia
YIM Oral
Poster
Favorite
1204
EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion
YIM Oral Poster
Poster
Favorite
1205
Investigating the eEF2K/eEF2 axis as a potential target in CLL following nelfinavir treatment
YIM Oral Poster
Poster
Favorite
1206
Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL
YIM Oral Poster
Poster
Favorite
1207
In vitro investigation of the phenotype of CLL cells during trafficking and homing in a 3D-printed bioreactor
Poster
Favorite
1208
Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people
Poster
Favorite
1209
Early effects of venetoclax monotherapy on immune cells in patients with chronic lymphocytic leukemia
Oral Poster
YIM Oral
Poster
Favorite
1210
Imaging mass cytometry reveals distinct cellular architectures in proliferative and non-proliferative regions of the chronic lymphocytic leukaemia lymph node tumour microenvironment
YIM Oral Poster
Poster
Favorite
1211
Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles
Poster
Favorite
1212
High-dimensional profiling of CLL and T cell interactions during early phase of disease using a 42-color full-spectrum cytometry panel
Poster
Favorite
1213
Characterizing the Tumor Microenvironment in CLL: The Role of NK Cells and Prognostic Gene Markers
Poster
Favorite
1214
CD49d promotes T cell senescence in chronic lymphocytic leukemia
Poster
Favorite
1215
Expression and signalling patterns of CD180/MD1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells and MEC 1 cell line
Poster
Favorite
1216
BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.
Poster
Favorite
1217
IGHV Repertoire in Israeli CLL Patients Reveals Significant Low Frequency of Stereotyped Subsets – A Single Center Retrospective Study
Poster
Favorite
1218
CD11c: A Promising Indicator for Zanubrutinib Efficacy Evaluation in High-Risk CLL
Poster
Favorite
1219
The immunogenicity landscape of CLL and its association with patient outcome
Poster
Favorite
1220
Chronic Lymphocytic Leukemia and Renal Cell Carcinoma: A Case Series of Twelve Patients
Poster
Favorite
1221
The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression
Poster
Favorite
1223
Depletion of normal B-cells, defined as < 20 cells/µL by high-sensitivity analysis, identifies early-stage CLL and MBL patients at increased risk of severe infection and early mortality.
Poster
Favorite
1224
A fraction of lymph node CLL B cells exhibits high expression of T-bet
Poster
Favorite
1225
Screening People with Persistent Absolute Lymphocytosis Favors the Identification of High-Count Monoclonal B-Cell Lymphocytosis
Poster
Favorite
1226
Ibrutinib enhances the bias of T-cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Poster
Favorite
1227
Clinical and Biological Impact of Plasma Cytokine Levels in Newly Diagnosed Chronic Lymphocytic Leukemia
Poster
Favorite
1301
Selective NIK Inhibition Overcomes Microenvironment-Mediated Resistance and Synergizes with Venetoclax in CLL
Poster
Favorite
1302
Pevonedistat Enhances the Cytotoxic Effect of Rohinitib on B Cells of Chronic Lymphocytic Leukemia
Poster
Favorite
1303
Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment
Oral Poster
YIM Oral Poster
Poster
Favorite
1304
Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family
Poster
Favorite
1305
CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
Oral Poster
Poster
Favorite
1306
Distinctive Features in NF-kB Regulation Favor a Synergistic Action of Pevonedistat and Laduviglusib on B Cells of Chronic Lymphocytic Leukemia
Poster
Favorite
1307
Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia
Poster
Favorite
1309
Effects of Pirtobrutinib, a non-covalent BTK inhibitor, on T-cell function in chronic lymphocytic leukemia (CLL)
Poster
Favorite
1310
Evaluation of two novel Cyclin Dependent Kinase 9 inhibitors for the treatment of Myeloid Cell Leukaemia 1 (MCL1) high Chronic Lymphocytic Leukaemia
Poster
Favorite
1311
Targeted Degradation of NF-κB RelA/p65 by PBD-Based PROTACs as a Novel Therapeutic Strategy in Chronic Lymphocytic Leukaemia
Oral
Favorite
1312
Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL
Oral
Favorite
1401
Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving First-line Therapy: A Real-World Study
Poster
Favorite
1402
Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
Poster
Favorite
1403
Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study
Poster
Favorite
1404
A Phase 2 study with Tafasitamab and Zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – TaZa CLL Study
Poster
Favorite
1406
Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group
Poster
Favorite
1407
The impact of body mass index on overall survival in chronic lymphocytic leukemia
Poster
Favorite
1408
Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen
Poster
Favorite
1409
Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study
Poster
Favorite
1410
Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
Poster
Favorite
1411
Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study
Poster
Favorite
1412
Real-world Utilization of Novel Therapies and Overall Survival among U.S. Medicare Beneficiaries Initiating Frontline Chronic Lymphocytic Leukemia Treatment
Poster
Favorite
1413
A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Poster
Favorite
1414
Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
Poster
Favorite
1415
Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial
Poster
Favorite
1416
CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Poster
Favorite
1417
Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety
Poster
Favorite
1418
A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy
Poster
Favorite
1419
SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Poster
Favorite
1420
Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Poster
Favorite
1421
Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study
Poster
Favorite
1422
Risk of Acute Kidney Injury and Cytopenias During Treatment of Chronic Lymphocytic Leukemia in a Nationwide Real-World Cohort
Poster
Favorite
1423
MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)
Poster
Favorite
1424
Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial
Poster
Favorite
1425
IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Poster
Favorite
1426
Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study
Poster
Favorite
1427
A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL)
Poster
Favorite
1428
A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
Poster
Favorite
1429
Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)
Poster
Favorite
1430
Assessing measurable residual disease (MRD) by cell-free DNA (cfDNA): results from a real-world series
Poster
Favorite
1431
The role of Minimal Residual Disease in chronic lymphocytic leukemia
Poster
Favorite
1432
Title: A phase Ib study evaluating the safety and efficacy of tafasitamab, acalabrutinib, and obinutuzumab (TAO) in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
Poster
Favorite
1433
Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.
Poster
Favorite
1434
STATIC TRIAL (Stopping Therapy to Avoid Treatment-resistance In CLL): A randomised phase III trial comparing intermittent with continuous treatment strategies in CLL
Poster
Favorite
1435
Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL
Poster
Favorite
1436
Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity
Poster
Favorite
1437
Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial
Poster
Favorite
1438
Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Oral Poster
Poster
Favorite
1439
Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)
Oral Poster
YIM Oral Poster
Poster
Favorite
1440
Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax
Oral Poster
Poster
Favorite
1441
A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Oral Poster
Poster
Favorite
1442
NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Oral
Favorite
1501
EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL-WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP
YIM Oral Poster
Poster
Favorite
1502
Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi
Poster
Favorite
1503
Analysis of resistance-related mutations in patients with Chronic Lymphocytic Leukemia treated with BTK or BCL2 inhibitors suggests different underlying resistance mechanisms and subclonal dynamics
YIM Oral
Poster
Favorite
1504
What measure of treatment effect should be preferred ? A critical review of 20 randomized clinical trials of targeted therapies in chronic lymphocytic leukemia
Poster
Favorite
1505
A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas
Poster
Favorite
1506
Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study
Poster
Favorite
1507
Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
Poster
Favorite
1508
Measurable Residual Disease in Chronic Lymphocytic Leukemia (CLL) in Clinical Practice: A Single-Center Report Over the Years 2018–2024
Poster
Favorite
1509
Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study
Poster
Favorite
1510
BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Poster
Favorite
1511
Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study
Poster
Favorite
1512
Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress
Poster
Favorite
1513
Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated with Rituximab-Venetoclax in real world: Insights from the "Dedalus" Protocol
Poster
Favorite
1514
Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses
Poster
Favorite
1515
Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Poster
Favorite
1516
Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025
Poster
Favorite
1517
Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis
Poster
Favorite
1518
Ultrasound assessment of chronic lymphocytic patients during BTK treatment: comparison of dimensional response vs overall ultrasound assessment in general practice. Preliminary results of a prospective study
Poster
Favorite
1519
Clinical and pharmacoeconomic impact of ultrasound assessment of patients with chronic lymphocytic leukemia treated with BTK inhibitors (BTKi)
Poster
Favorite
1520
Unveiling the journey of Chronic Lymphocytic Leukemia patients in Portugal: insights into the Rituximab-Venetoclax protocol
Poster
Favorite
1521
Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study
Poster
Favorite
1522
MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Poster
Favorite
1523
SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety/Efficacy of AZD0486 as Monotherapy or in Combination With Acalabrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Poster
Favorite
1524
Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study
Poster
Favorite
1525
Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Poster
Favorite
1526
Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry
Poster
Favorite
1527
Ibrutinib can be effective even at the lowest dose after 10 years of treatment
Poster
Favorite
1528
Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States
Poster
Favorite
1529
Prevalence of BTK, PLCG2, and BCL2 mutations in CLL patients in Croatia - KROHEM study
Poster
Favorite
1601
Central Nervous System Involvement in Patients with Richter Transformation
YIM Oral
Poster
Favorite
1602
Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience
YIM Oral
Poster
Favorite
1603
Single-cell transcriptome analysis reveals molecular mechanism of stem-like cells in Richter Transformation
YIM Oral
Poster
Favorite
1604
The CDK2/9 inhibitor fadraciclib in Richter transformation
Poster
Favorite
1605
Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter’s transformation - NCT05672173
Poster
Favorite
1606
Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial
Oral
Favorite
1607
MGA Loss drives cristae remodeling and redox adaptation via MICOS and PRDX2 in Richters transformation
Oral
Favorite
1701
Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data
YIM Oral Poster
Poster
Favorite
1702
Immune Cytopenia with Chronic Lymphocytic Leukemia: A Real-World Clinical Characteristic Analysis
Poster
Favorite
1703
Targeting immunoglobulin deficiency in CLL: A retrospective evaluation of IgM/IgA-enriched IVIg use in a small cohort of patients from Argentina
Poster
Favorite
1704
Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
Poster
Favorite
1705
Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group
Poster
Favorite
1706
A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology
Poster
Favorite
1707
Evaluating CLL/SLL Clinical Trials: A Participation-to-Prevalence Analysis Using Institutional and SEER Data from 2012-2024
Poster
Favorite
1708
Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
Poster
Favorite
1709
Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Poster
Favorite
1710
A nomogram for survival prediction based on socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database
Poster
Favorite
1711
A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.
Poster
Favorite
1712
Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Poster
Favorite
1713
An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.
Poster
Favorite
1714
Trends and Predictors of Engagement in Preventive Health Measures in Patients with Chronic Lymphocytic Leukemia: A Prospective Analysis of Vaccinations and Cancer Screening Practices
Poster
Favorite
1715
Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies
Poster
Favorite
1716
Incidence of second primary malignancies in Chronic lymphocytic leukemia
Poster
Favorite
1717
MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study
Oral Poster
Poster
Favorite
1801
Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
Oral Poster
YIM Oral
Poster
Favorite
1802
Targeting SF3B1 Disrupts Chronic Lymphocytic Leukemia Survival via PFKFB-mediated Glycolytic Dependency
Oral Poster
YIM Oral
Poster
Favorite
1803
Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Poster
Favorite
1804
BRD4 maintains the surface phenotype of Chronic Lymphocytic Leukemia cells
Poster
Favorite
1805
Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia
Poster
Favorite
1806
Dual mTORC1/2 Inhibition by Torin 2 Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Chronic Lymphocytic Leukaemia
Poster
Favorite
1807
Therapeutical potential of NRF2 inhibition by Brusatol in Chronic lymphocytic leukemia and in combination with current therapy
Poster
Favorite
1808
Setting a 3D model to study Chronic Lymphocytic Leukemia
Poster
Favorite
1901
Similarities and Differences in Immune Modulation by Acalabrutinib and Zanubrutinib in Chronic Lymphocytic Leukemia
Poster
Favorite
1902
Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study
Oral Poster
Poster
Favorite
1903
Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of
Bispecific Antibodies in CLL
Poster
Favorite
1904
Development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL, including in patients treated with anti-CD19 antibody tafasitamab
Poster
Favorite
1905
Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation
Poster
Favorite
1906
Fibroblast mediated Modulation of bispecific Antibody Treatment in Chronic Lymphocytic Leukemia
Poster
Favorite
1907
Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.
Poster
Favorite
1908
Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
Poster
Favorite
1909
A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)
Poster
Favorite
1910
Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)
Poster
Favorite
1911
Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making
Poster
Favorite
1912
A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in chronic lymphocytic leukemia
Oral
Favorite
2001
Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
Poster
Favorite
2002
Improving information provision to enhance chronic lymphocytic leukaemia (CLL) care in resource-limited countries
Poster
Favorite
2003
Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs
Poster
Favorite
2004
Clinicopathological Features and Treatment Outcomes of Chronic Lymphocytic Leukemia in Pakistan: A Real-World Analysis
Oral
Favorite
2005
Expression of TP53 deletion and Clinical Presentations of Nigerians with Chronic Lymphocytic Leukaemia: A Preliminary Report
Poster
Favorite
2006
Understanding the unmet needs in diagnostics and therapeutics of chronic lymphocytic leukemia in Korea
Poster
Favorite
LB01
A Rare Case of t(8;16)(p11.2;p13.3) and del(17p) That Shows Both Acute Myeloid Leukaemia and Chronic Lymphocytic Leukaemia at the Same Time
Poster
Favorite
LB02
Efficacy of Fludarabine-based Regimen in the Treatment of Chronic Lymphocytic Leukaemia: A 10-year Comparative Analysis from a Resource-Limited Setting
Poster
Favorite
LB03
Exploration of Early Signalling Events of CLL upon Exposure to Low Dose Combination of Ibrutinib and Venetoclax
Poster
Favorite
LB04
Factors predicting pulmonary infections in chronic lymphocytic leukemia (CLL) treated with targeted therapies with a history of lung diseases: factors are IGHV, TP53 (low and high burden) and COBBLL1
Poster
Favorite
LB05
Integrated immunogenetic and cytogenetic profiling reveals distinct biological patterns among stereotyped BCR subsets in CLL
Poster
Favorite
LB06
Investigating 17p-Deletion in Chronic Lymphocytic Leukaemia: A Study of Tumour-Suppressive microRNAs
Poster
Favorite
LB07
Risk Stratification in Chronic Lymphocytic Leukemia by IgHV Status and Mutational Co-Occurrence Profiling
Poster
Favorite
LB08
Secondary factors in chronic lymphocytic leukemia (CLL) such as COBBLL1 and response prediction in TP53 non-mutant cohort treated with single agent venetoclax or Obinutuzumab
Poster
Favorite
LB09
XPO1 Inhibitor Selinexor Induces Heme Oxygenase-1 Mediated p53-Dependent Mitochondrial Ferroptosis in Chronic Lymphocytic Leukemia
Poster
Favorite
